ICCC · ImmuCell Corporation Common Stock
View on chartInsiders & Stakes
| Michael F. Brigham Director | ▼ Sell | Tax Withholding | 205,700 Shares held | 3/20/2026 | View profile |
| CRABB JOSEPH H Former VP and CSO | ▼ Sell | Other | 142,845 Shares held | 3/9/2022 | View profile |
| Boekhorst Paul Francis Olivier te President and CEO | ▲ Buy | Open Market | 17,785 Shares held | 6/18/2026 | View profile |
| Cunningham David | ▲ Buy | Open Market | 16,000 Shares held | 6/13/2022 | View profile |
| David Scott Tomsche | ▲ Buy | Open Market | 4,740 Shares held | 11/25/2025 | View profile |
| Gloria F. Basse | ▲ Buy | Option Exercise | 3,530 Shares held | 6/11/2025 | View profile |
| Bryan K. Gathagan | ▲ Buy | Open Market | 1,000 Shares held | 6/12/2025 | View profile |
Transaction History
| Boekhorst Paul Francis Olivier te | ▲ Buy | Open Market | 8,000 | $76K | 6/18/2026 |
| Michael F. Brigham | ▲ Buy | Option Exercise | 25,000 | $146K | 3/20/2026 |
| Michael F. Brigham | ▼ Sell | Tax Withholding | 24,052 | $146K | 3/20/2026 |
| Boekhorst Paul Francis Olivier te | ▲ Buy | Open Market | 3,521 | $18K | 12/3/2025 |
| Boekhorst Paul Francis Olivier te | ▲ Buy | Open Market | 2,556 | $13K | 12/3/2025 |
| Boekhorst Paul Francis Olivier te | ▲ Buy | Open Market | 3,708 | $18K | 12/2/2025 |
| David Scott Tomsche | ▲ Buy | Open Market | 1,633 | $8K | 11/25/2025 |
| David Scott Tomsche | ▲ Buy | Open Market | 1,633 | $8K | 11/25/2025 |
| Bryan K. Gathagan | ▲ Buy | Open Market | 1,000 | $6K | 6/12/2025 |
| Gloria F. Basse | ▲ Buy | Option Exercise | 3,530 | $17K | 6/11/2025 |
| David Scott Tomsche | ▼ Sell | Other | 2,186 | $8K | 8/28/2024 |
| David Scott Tomsche | ▼ Sell | Other | 6,005 | $21K | 8/23/2024 |
| David Scott Tomsche | ▼ Sell | Other | 10,000 | $36K | 8/22/2024 |
| David Scott Tomsche | ▼ Sell | Other | 3,172 | $12K | 8/19/2024 |
| David Scott Tomsche | ▼ Sell | Other | 4,811 | $18K | 8/16/2024 |
| David Scott Tomsche | ▼ Sell | Other | 2,017 | $7K | 8/15/2024 |
| David Scott Tomsche | ▼ Sell | Other | 3,100 | $15K | 9/6/2023 |
| David Scott Tomsche | ▼ Sell | Other | 71 | $391 | 3/14/2023 |
| David Scott Tomsche | ▼ Sell | Other | 309 | $2K | 3/14/2023 |
| David Scott Tomsche | ▼ Sell | Other | 31 | $171 | 3/14/2023 |
| David Scott Tomsche | ▼ Sell | Other | 69 | $382 | 3/14/2023 |
| David Scott Tomsche | ▼ Sell | Other | 31 | $171 | 3/14/2023 |
| David Scott Tomsche | ▼ Sell | Other | 69 | $382 | 3/14/2023 |
| David Scott Tomsche | ▼ Sell | Other | 31 | $171 | 3/14/2023 |
| David Scott Tomsche | ▼ Sell | Other | 69 | $382 | 3/14/2023 |
| David Scott Tomsche | ▼ Sell | Other | 69 | $382 | 3/14/2023 |
| David Scott Tomsche | ▼ Sell | Other | 100 | $553 | 3/14/2023 |
| David Scott Tomsche | ▼ Sell | Other | 69 | $382 | 3/14/2023 |
| David Scott Tomsche | ▼ Sell | Other | 100 | $544 | 3/14/2023 |
| David Scott Tomsche | ▼ Sell | Other | 31 | $171 | 3/14/2023 |
| David Scott Tomsche | ▼ Sell | Other | 100 | $553 | 3/14/2023 |
| David Scott Tomsche | ▼ Sell | Other | 831 | $5K | 3/14/2023 |
| David Scott Tomsche | ▼ Sell | Other | 400 | $2K | 3/13/2023 |
| David Scott Tomsche | ▼ Sell | Other | 300 | $2K | 3/13/2023 |
| David Scott Tomsche | ▼ Sell | Other | 200 | $1K | 3/13/2023 |
| David Scott Tomsche | ▼ Sell | Other | 900 | $5K | 3/13/2023 |
| David Scott Tomsche | ▼ Sell | Other | 80 | $427 | 3/13/2023 |
| David Scott Tomsche | ▼ Sell | Other | 3 | $16 | 3/13/2023 |
| David Scott Tomsche | ▼ Sell | Other | 7 | $37 | 3/13/2023 |
| David Scott Tomsche | ▼ Sell | Other | 10 | $52 | 3/13/2023 |
| David Scott Tomsche | ▼ Sell | Other | 100 | $524 | 3/13/2023 |
| David Scott Tomsche | ▼ Sell | Other | 100 | $524 | 3/13/2023 |
| David Scott Tomsche | ▼ Sell | Other | 606 | $5K | 9/12/2022 |
| David Scott Tomsche | ▼ Sell | Other | 195 | $2K | 9/12/2022 |
| David Scott Tomsche | ▼ Sell | Other | 20 | $154 | 9/9/2022 |
| David Scott Tomsche | ▼ Sell | Other | 647 | $5K | 9/9/2022 |
| David Scott Tomsche | ▼ Sell | Other | 33 | $257 | 9/9/2022 |
| David Scott Tomsche | ▼ Sell | Other | 306 | $2K | 9/8/2022 |
| David Scott Tomsche | ▼ Sell | Other | 329 | $3K | 9/8/2022 |
| David Scott Tomsche | ▼ Sell | Other | 5 | $39 | 9/8/2022 |
| David Scott Tomsche | ▼ Sell | Other | 5 | $39 | 9/8/2022 |
| David Scott Tomsche | ▼ Sell | Other | 260 | $2K | 9/8/2022 |
| David Scott Tomsche | ▼ Sell | Other | 1 | $8 | 9/8/2022 |
| David Scott Tomsche | ▼ Sell | Other | 50 | $403 | 6/14/2022 |
| David Scott Tomsche | ▼ Sell | Other | 400 | $3K | 6/14/2022 |
| David Scott Tomsche | ▼ Sell | Other | 200 | $2K | 6/14/2022 |
| David Scott Tomsche | ▼ Sell | Other | 485 | $4K | 6/13/2022 |
| Cunningham David | ▲ Buy | Open Market | 1,000 | $8K | 6/13/2022 |
| David Scott Tomsche | ▼ Sell | Other | 462 | $4K | 6/13/2022 |
| David Scott Tomsche | ▼ Sell | Other | 90 | $701 | 6/13/2022 |
| David Scott Tomsche | ▼ Sell | Other | 200 | $2K | 6/13/2022 |
| David Scott Tomsche | ▼ Sell | Other | 200 | $2K | 6/13/2022 |
| David Scott Tomsche | ▼ Sell | Other | 48 | $375 | 6/13/2022 |
| David Scott Tomsche | ▼ Sell | Other | 87 | $736 | 6/9/2022 |
| David Scott Tomsche | ▼ Sell | Other | 70 | $594 | 6/9/2022 |
| David Scott Tomsche | ▼ Sell | Other | 643 | $5K | 6/9/2022 |
| David Scott Tomsche | ▼ Sell | Other | 500 | $4K | 6/9/2022 |
| David Scott Tomsche | ▼ Sell | Other | 200 | $2K | 6/9/2022 |
| David Scott Tomsche | ▼ Sell | Other | 53 | $434 | 6/7/2022 |
| David Scott Tomsche | ▼ Sell | Other | 112 | $918 | 6/2/2022 |
| David Scott Tomsche | ▼ Sell | Other | 300 | $2K | 6/1/2022 |
| David Scott Tomsche | ▼ Sell | Other | 100 | $827 | 6/1/2022 |
| David Scott Tomsche | ▼ Sell | Other | 700 | $6K | 6/1/2022 |
| David Scott Tomsche | ▼ Sell | Other | 3,400 | $28K | 5/17/2022 |
| David Scott Tomsche | ▼ Sell | Other | 200 | $2K | 5/16/2022 |
| CRABB JOSEPH H | ▼ Sell | Other | 1,000 | $6K | 3/9/2022 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
ICCC featured in research roundup alongside major tech and pharma names
ImmuCell Corporation was included in a recent Yahoo Finance article highlighting top research reports for Alphabet, Mastercard, and AbbVie. This mention places ICCC in the same discussion as large-cap companies, though the specific details of the research for ICCC are not provided in the summary. The stock currently trades within its 52-week range, with a trailing P/E of 115.1.
ICCC featured in research roundup alongside major tech and pharma names. ImmuCell Corporation was included in a recent Yahoo Finance article highlighting top research reports for Alphabet, Mastercard, and AbbVie. This mention places ICCC in the same discussion as large-cap companies, though the specific details of the research for ICCC are not provided in the summary. The stock currently trades within its 52-week range, with a trailing P/E of 115.1.